- What's Tisch?
- Stem Cell Trial
- Get Involved
Last week, our researchers and physicians discussed a paper regarding the association of higher Ocrelizumab exposure with reduced disability progression in MS. Ocrelizumab, or Ocrevus, is a prescription drug commonly used to treat both progressive and relapsing-remitting MS. Ocrelizumab was shown to reduce new MRI lesion counts, and resulted in a lower annual relapse rate in RRMS patients. These findings suggest that higher exposure to Ocrelizumab may result in improved control of disability progression.
#tischms #curems #findacureforMS #tischMSRCNY